Stranger Things: New Roles and Opportunities for Androgen Receptor in Oncology Beyond Prostate Cancer

Authors

Javier Leo
Eleonora Dondossola
Kaitlin J Basham
Nathaniel R Wilson
Omar Alhalabi
Jianjun Gao
Katherine C Kurnit
Michael G White
Jennifer L McQuade
Shannon N Westin
Elizabeth A Wellberg
Daniel E Frigo

Publication Date

4-17-2023

Journal

Endocrinology

Abstract

The androgen receptor (AR) is one of the oldest therapeutic targets in oncology and continues to dominate the treatment landscape for advanced prostate cancer, where nearly all treatment regimens include some form of AR modulation. In this regard, AR remains the central driver of prostate cancer cell biology. Emerging preclinical and clinical data implicate key roles for AR in additional cancer types, thereby expanding the importance of this drug target beyond prostate cancer. In this mini-review, new roles for AR in other cancer types are discussed as well as their potential for treatment with AR-targeted agents. Our understanding of these additional functions for AR in oncology expand this receptor's potential as a therapeutic target and will help guide the development of new treatment approaches.

Keywords

androgen receptor, prostate cancer, breast cancer, endometrial cancer, adrenal cancer, melanoma, bladder cancer, liver cancer

Comments

PMID: 37154098